Irvine Scientific adds new Center of Excellence for R&D
Company adds fifth building in Southern California.
Irvine Scientific has announced the expansion of its Orange County, California offices and laboratories, with the addition of a 40,000 sq. ft purpose-built R&D center at 17112 Armstrong Ave, Irvine, California. The growth of the company is in response to increased customer demand for Irvine Scientific’s cell culture and media reagents, and follows the significant expansion of its R&D facilities less than 5 years ago.
The new building will also contain other departments that currently reside within its southern California based headquarters enabling the company to expand other capabilities, such as media customization for customers, conducted at its headquarters in Santa Ana. Along with the other facilities in Santa Ana, CA this increases the total space occupied by Irvine Scientific in Orange County to over 140,000 sq. ft.
“This addition allows us to continue our expansion of R&D, which supports our longer-term strategy of maintaining a leadership position of innovation in cell culture media and reagents,” said Tim Mullane, Chief Operating Officer. “Additional capacity will allow us to expand our space and staff dedicated to advancing cell culture technology important to our customers. Along with this growth we will continue to advance our analytical capabilities and services to our customers.”
Customers producing biologicals, vaccines, and cell-based therapies often require expert assistance from the company’s scientists and experts to modify and optimize the cell culture conditions during various stages of a program’s development. With the opening of the new facility, Irvine Scientific plans to expand the laboratories and staff located in its main Headquarters that are dedicated to providing these services to customers.
Tim Mullane added: “While the R&D capability expands, the space dedicated to our Express Media Services within our corporate HQ location will expand. This group currently supports our biopharmaceutical and cell therapy customers and has experienced dramatic growth in the last several years.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance